These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 16428478

  • 1. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
    Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K.
    Clin Cancer Res; 2006 Jan 15; 12(2):398-404. PubMed ID: 16428478
    [Abstract] [Full Text] [Related]

  • 2. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ.
    Cancer Res; 2003 Sep 15; 63(18):6076-83. PubMed ID: 14522938
    [Abstract] [Full Text] [Related]

  • 3. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.
    Ayyoub M, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D.
    J Clin Invest; 2004 Apr 15; 113(8):1225-33. PubMed ID: 15085202
    [Abstract] [Full Text] [Related]

  • 4. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.
    Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D.
    Clin Immunol; 2005 Jan 15; 114(1):70-8. PubMed ID: 15596411
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D.
    Cancer Res; 2003 Sep 01; 63(17):5601-6. PubMed ID: 14500401
    [Abstract] [Full Text] [Related]

  • 7. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
    Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S.
    Proc Natl Acad Sci U S A; 2007 Jul 31; 104(31):12837-42. PubMed ID: 17652518
    [Abstract] [Full Text] [Related]

  • 8. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
    He Y, Mao L, Lin Z, Deng Y, Tang Y, Jiang M, Li W, Jia Z, Wang J, Ni B, Wu Y.
    Mol Immunol; 2008 May 31; 45(9):2455-64. PubMed ID: 18295890
    [Abstract] [Full Text] [Related]

  • 9. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.
    Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M.
    Clin Immunol; 2006 Oct 31; 121(1):54-62. PubMed ID: 16814609
    [Abstract] [Full Text] [Related]

  • 10. Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.
    Godefroy E, Wang Y, Souleimanian NE, Scotto L, Stevanovic S, Chen YT, Valmori D, Ayyoub M.
    Cancer Immunol Immunother; 2007 Aug 31; 56(8):1183-92. PubMed ID: 17186289
    [Abstract] [Full Text] [Related]

  • 11. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
    Qian F, Gnjatic S, Jäger E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter G, Lele S, Sood A, Old LJ, Odunsi K.
    Cancer Immun; 2004 Nov 03; 4():12. PubMed ID: 15521719
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanoviç S, Wallwiener D, Gückel B.
    Clin Cancer Res; 2003 Oct 01; 9(12):4376-86. PubMed ID: 14555509
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
    Lu Y, Wu LQ, Lü ZH, Wang XJ, Yang JY.
    Chin Med J (Engl); 2007 Jun 20; 120(12):1042-6. PubMed ID: 17637219
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E.
    Clin Cancer Res; 2006 Mar 15; 12(6):1921-7. PubMed ID: 16551878
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
    Wen W, Zhang L, Peng J, Chen J, Hao J, Li X, Qian X, Zeng P, Zhang Y, Yin Y.
    Cancer Sci; 2011 Aug 15; 102(8):1455-61. PubMed ID: 21595801
    [Abstract] [Full Text] [Related]

  • 20. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM.
    Cancer Res; 2002 Jan 01; 62(1):213-8. PubMed ID: 11782380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.